How the body processes a new leukemia drug

Plain-English translation of NCT07295951 on ClinicalTrials.gov ↗ · Source last updated July 2026 · Translation generated August 2026 · How we translate trials

Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.

What is this trial?

This study is testing a new medication called for people with acute leukemia that has not responded to other treatments or has come back after treatment. Researchers will use a special radioactive version of the medication to track exactly how your body absorbs, breaks down, and removes it. This information will help them understand the best way to use this treatment in future patients.

Doctors need to understand how new medications move through the body so they can figure out the right doses and know what to expect in terms of side effects. This type of tracking study is an important early step in proving whether a promising new treatment is safe and effective enough to test more broadly.

Do you qualify?

You likely qualify if…

you have been diagnosed with acute leukemia (a fast-growing blood cancer) that has either returned after treatment or did not respond to previous treatments
your leukemia has specific genetic mutations (changes in genes called KMT2A, NPM1, NUP98, or NUP214) and you have run out of other treatment options or are not eligible for them
you weigh at least 40 kilograms (about 88 pounds)
you are generally healthy enough for treatment, with a good ability to perform daily activities
you have regular bowel movements (at least one every 2 days)

You likely don't qualify if…

you have acute promyelocytic leukemia or Down syndrome-related leukemia
you have active leukemia in your brain or central nervous system
you have had a solid organ transplant
you have ongoing side effects from previous cancer treatments that have not improved to mild levels or resolved
you have had major surgery within the past 2 weeks or are planning major surgery during the study

What participation looks like

You will start by taking a single dose of the radioactive form of the medication on Day 1 of the study, which helps researchers track how your body processes it. Starting on Day 2, you will take the regular (non-radioactive) form of the medication daily for the rest of the first month-long cycle. If you tolerate the treatment well, you may be eligible to continue in a follow-up study where you can keep receiving the medication for as long as it is helping you.

AI-generated summary from trial data · Aug 14, 2026 · Not medical advice

Trial locations(1 site)

United Kingdom

The Christie NHS Foundation Trust Christie Hospital, Manchester